TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
Transcenta, Biologics, Antibody, Claudin 18.2
2015 - 05 - 21
SUZHOU, China--(BUSINESS WIRE)--MabSpace Biosciences Co., Ltd announced today that it has signed a collaborative contract of a novel therapeutic antibody with Genor Biopharma Co. Ltd (GenorBio), the mAb division of Walvax Group, one of the leading therapeutic antibody development companies in China.
According to the agreement, MabSpace will be responsible for the discovery and selection of fully human lead antibodies and GenorBio for the further development of the selected candidate molecules. GenorBio will own exclusive global rights on the resulting therapeutic candidates for the nominated targets, while MabSpace will receive upfront R&D funding, regulatory milestones and royalty on global sales.
“We are attracted by MabSpace’s capability in discovering novel differentiated antibody therapeutic candidates with its immune tolerance breaking technology and the access to fully human antibody transgenic mice platform,” commented Dr. Joe Zhou, CEO of Genor Biopharma and VP of Research of Walvax Group.
“MabSpace is honored to work with GenorBio who has extensive capabilities and experience in antibody process and product development,” said Dr. Xueming Qian, Chairman and CEO of MabSpace.
About Walvax and GenorBio
Walvax is the first vaccine company listed on ChiNext. Since its historical IPO in 2010, Walvax has expanded and built itself into a leading and fully integrated biopharmaceutical group, with its business covering vaccines, mAbs and blood-derived products. Walvax acquired Genor at the end of 2013 as a major strategic move.
Founded in 2007, Genor Biopharma Co. Ltd. is an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibodies (mAbs) and Fc-fusion proteins. Visit www.genorbio.com for more information.
FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab (TST001) as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients
Transcenta Anti-sclerostin Monoclonal Antibody TST002 (Blosozumab) Received Approval from China CDE to Initiate Phase II Clinical Trial in Patients with Reduced Bone Mineral Density
Transcenta Received Approvals from China CDE and South Korea MFDS to Initiate TranStar 301 Global Phase III Pivotal Trial of Osemitamab (TST001)
Transcenta Presented PFS Data by CLDN18.2 Expression Level from Phase I/II Study of Osemitamab (TST001) plus CAPOX as the First-Line Treatment of Advanced G/GEJ Cancer at 2023 ESMO GI Annual Congress
Transcenta Presents Updated Data of Osemitamab (TST001) in Combination with CAPOX as a First-Line Treatment of G/GEJ Cancer at 2023 ASCO Annual Meeting
Transcenta Announces Encouraging Phase I Clinical Data of TST002 (Blosozumab) in Chinese Patients with Reduced Bone Mineral Density